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ORIGINAL ARTICLE
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Lund, Sweden; cRegional Cancer Centre Stockholm Gotland, Stockholm, Sweden; dCentral Hospital of Kristianstad, Region Skåne,
Kristianstad, Sweden; eCREATE Health, Faculty of Engineering LTH, Lund University, Lund, Sweden; fInstitute of Clinical Sciences, Division of
Oncology and Pathology, Lund University, Lund, Sweden; gClinical Research Centre Copenhagen University Hospital, Hvidovre, Denmark;
hDanish Cancer Society Research Center, Copenhagen, Denmark
ABSTRACT
Background: Fast-track referral is an increasingly used method for diagnostic evaluation of patients
suspected of having cancer. This approach is challenging and not used as often for patients with only
nonspecific symptoms. In order to expedite the diagnostics for these patients, we established
Sweden’s first Diagnostic Center (DC) focusing on outcomes related to diagnoses and diagnostic
time intervals.
Material and Methods: The study was designed as a prospective cohort study. Patients aged 18
years who presented in primary care with nonspecific symptoms of a serious disease were eligible for
referral to the DC after having completed an initial investigation. Acceptable diagnostic time intervals
were defined to be a maximum of 15 days in primary care and 22 days at the DC. Diagnostic out-
come, length of diagnostic time intervals and patient satisfaction were evaluated.
Results: A total of 290 patients were included in the study. Cancer was diagnosed in 22.1%, other dis-
eases in 64.1%, and no diagnosis was identified in 13.8% of these patients. Patients diagnosed with
cancer were older, had shorter patient interval (time from first symptom to help-seeking), shorter DC-
interval (time from referral decision in primary care to diagnosis) and showed a greater number of
symptoms compared to patients with no diagnosis. The median primary care interval was 21 days and
the median DC interval was 11 days. Few symptoms, no diagnosis, female sex, longer patient interval,
and incomplete investigations were associated with prolonged diagnostic time intervals. Patient satis-
faction was high; 86% of patients reported a positive degree of satisfaction with the diagnos-
tic procedures.
Conclusions: We demonstrated that the DC concept is feasible with a diagnosis reached in 86.2% of
the patients in addition to favorable diagnostic time intervals at the DC and a high degree of patient
satisfaction.
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Introduction
Most patients who subsequently will be diagnosed with can-
cer have initially seen a family physician. Delayed diagnostics
increases the psychological burden for patients and has, in
several cancer types, been associated with an adverse prog-
nosis [1–5]. Hence, expedited referrals from family physicians
have the potential to positively influence survival rates in a
number of cancer types [6]. Interventions to reduce diagnos-
tic time intervals need to address patient-related as well as
system-related factors; this has been documented in a com-
parative study between England, Denmark and Sweden [7].
To achieve expedited diagnoses and more timely initiation of
treatment, diagnostic pathways for patients with a prede-
fined set of symptoms have been implemented in several
countries. Fast-track referral pathways for patients with sus-
pected cancer were introduced in the UK in the early 2000’s
and similar systems (referred to as cancer patient pathways)
were introduced in Denmark in 2008 and in Norway in 2015
[8–10]. Although Sweden, in a global comparison, has one of
the highest cancer survival rates [11,12], the healthcare sys-
tem lags behind in international benchmarking evaluations;
this can largely be explained by insufficient access to care,
long diagnostic time intervals, and suboptimal patient satis-
faction reports [13] Awareness of these issues led to the
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implementation of 28 standardized care pathways for cancer
between 2015 and 2018 [14].
Fast-track referral is typically based on alarm symptoms
such as macroscopic hematuria, rectal bleeding or a lump in
the breast, but only about half of the patients in primary
care showed such symptoms [15,16]. In primary care, many
patients with cancer show only general or nonspecific symp-
toms, such as fatigue, weight-loss, fever, or anemia [16,17]
and fast-track referral is less likely for these latter subgroups
[18]. Results from five case-control studies in the UK (the
CAPER studies) confirm that many patients with common
cancers do not have evident alarm symptoms, but low-risk
symptoms, and may thus not qualify for urgent referral [19].
Higher five-year mortality has been associated with non-
specific symptoms and prolonged diagnostic intervals for
lung cancer, malignant melanoma, and prostate cancer [5].
Thus, interventions directed at patients with nonspecific
symptoms are needed to reduce the time from first symptom
to diagnosis and subsequent treatment. In Denmark, the first
diagnostic center (DC) aimed at inter-disciplinary and inter-
sectorial patient pathways was initiated in 2009 followed by
further national implementation in 2012 [20,21]. In the UK, a
new Suspected CANcer (SCAN) pathway for patients with
‘low-risk but not no-risk’ is currently being evaluated [22].
Early positive reports from Denmark led us in 2011 to begin
developing a model for the first DC in Sweden. The project
group consisted of specialists in family medicine, clinical
chemistry, gynecology and obstetrics, pathology, radiology
and a nurse. Patients with a set of defined nonspecific symp-
toms were eligible for DC-investigation, which included a
standardized laboratory and radiology package. The time
goals for the investigations were decided in collaboration
with the primary healthcare centers and based on what
could be expected in optimal cases including reasonable
time intervals for laboratory analyses, biopsies, imaging and
consultations with other medical specialists. The aim of our
study was to investigate the diagnostic spectrum, diagnostic
time intervals, feasibility, and patient satisfaction at the DC.
Material and methods
Diagnostic center setting
The DC was physically established in October 2012 at the
Central Hospital of Kristianstad as a separate outpatient unit
within the Department of Internal Medicine. It was located
next-door to the Department of Radiology and Imaging thus
facilitating a close collaboration between the units. The DC
was staffed with a half-time physician specialized in internal
medicine and family medicine, a full-time nurse and a full-
time medical secretary. The catchment area initially com-
prised 25 primary healthcare centers and was gradually
extended to 42 centers; this encompassed a catchment area
of 220,000 inhabitants in the eastern part of the county.
Ensuring that family physicians were aware of the DC and
getting routines to work were identified as key factors in the
project planning and described in the risk analysis as likely risks
with serious consequences. A communication plan was devel-
oped in collaboration with the primary healthcare centers. The
implementation was then commenced in 2012 with information
meetings with family physicians and nurses. Written information
was distributed to all primary healthcare centers. The primary
care representative in the project group continued throughout
the study to visit the primary healthcare centers to remind staff
about the DC during the project.
Eligibility criteria
We performed a prospective cohort study of patients that had
been referred to the DC from primary care. Data collection was
initiated at the start and was scheduled to last until 60 patients
with cancer were included, which occurred in September 2015.
The stipulated goal of 60 patients with cancer was based on an
expectation of 300 patients needed for proper analyses of the
laboratory tests. At the time of project planning, preliminary
data from Denmark suggested a 20% prevalence of cancer,
which corresponds to 60 patients in our study.
At the first DC visit, all patients who could provide
informed consent based on oral and written study informa-
tion in Swedish were invited to participate in the study.
Reasons for exclusion were collected in a screening log that
was reviewed by a study nurse.
Family physicians were invited to refer patients 18 years
or older to the DC. Inclusion criteria were adopted from
Denmark and included one or more of the following criteria:
(1) fatigue, (2) weight loss more than 5 kg, (3) pain/joint
pain, (4) prolonged fever, (5) pathological lab values or (6)
suspected metastasis [23].
The complete diagnostic interval, from first contact with pri-
mary care to diagnosis, comprised of two phases: (1) the pri-
mary care interval, from first contact with primary care to
decision about referral to the DC and (2) the DC interval, from
referral decision in primary care to diagnosis. The terms
‘diagnostic interval’ and ‘primary care interval’ were modified
from The Aarhus statement 2012 [24].
The study was approved by the Regional Ethics Committee
in Lund, Sweden (registry number 2012/449) and was regis-
tered in ClinicalTrials.gov (registry number: NCT01709539).
Logistics of the diagnostic fast-track pathway
Primary care interval: diagnostic workup in primary care
(15 working days)
Patients in primary care that met one or more of the referral
criteria, without focal symptoms, were offered an appointment
with a family physician within two to three working days after
their first contact with the center. The investigation included a
medical history, a clinical examination and a standardized set
of laboratory tests. In cases when the diagnosis was still
unclear, these tests were followed by a second set of tests.
Diagnostic workup in primary care also included chest X-ray
and abdominal ultrasound to be scheduled within three work-
ing days from referral. If focal symptoms or signs of specific dis-
ease were found during the diagnostic workup in primary care,
the patients were referred to a respective medical specialist or
standardized care pathway. These patients were not included
in the study. If no reasonable explanation for the patient’s
symptoms was found, the patient was eligible for referral to
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the DC. This was done via phone call and written referral. In
conjunction with the referral, a standardized panel of laboratory
tests (the DC-package; Figure 1) was taken; the results were
sent directly to the DC.
DC interval: diagnostic workup at the DC (22
working days)
Patients should be offered an appointment with the DC-
physician within three working days post referral. Guided by
the medical history, the following were performed: a thor-
ough physical examination, evaluation of the results from
the DC-package and appropriate further investigations,
including consultations with other specialists. The aim of
these investigations was to have a resulting diagnosis within
22 working days. Upon evaluation at the DC being com-
pleted, the study participants were asked to fill in a question-
naire about individual profile, time from first symptoms to
first primary care contact, and patient-reported experiences.
Data collection
Data on time intervals, symptoms, investigations, comorbidity,
drugs, and diagnoses were collected and documented in case
report forms, which were monitored and validated by a study
nurse using original data from the patient’s files. Investigation
times were evaluated via a number of registration points dur-
ing the diagnostic trajectory (Figure 1). Phase 1 (primary care
interval) was defined as the time from first contact with primary
care until referral to the DC. Phase 2 (DC interval) was defined
as the time from referral decision at the primary healthcare
center to the date when the patient was informed about the
outcome of the diagnostic process and hence received a diag-
nosis. In individuals with multiple diagnoses, diagnostic time
intervals were calculated differently for patients with and with-
out cancer (stop date defined as the date of the latest diagno-
sis, or the date of first cancer diagnosis).
The symptoms that led to referral from the family physi-
cians were collected from the referrals. In the case report
forms, the DC-physician was able to comment on the investi-
gations. Documented reasons for prolonged investigation
times were categorized into six explanatory groups.
Statistical analysis
Age is presented as median and interquartile range (IQR),
while sex, education, marital status, country of birth and
Figure 1. The DC-process, overview. Expected time intervals and the DC-package.
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diagnoses at the DC are presented as numbers and percen-
tages. Investigation times are presented as mean and stand-
ard deviation (SD) together with percentiles. Number of days
refers to number of working days and the first day of the
interval (day zero) counts as one day. Fulfilment of time
goals were calculated as proportion that was investigated
within expected time frames. To examine differences
between patients diagnosed with cancer, patients diagnosed
with other diseases and patients with no diagnosis, we used
Chi-square test or Fishers exact test for the categorized varia-
bles and Wilcoxon rank-sum test for the other variables.
Corresponding tests were used to examine differences
between patients who fulfilled time goals and those who did
not, as well as between the 10% shortest and 10% longest
time intervals. Data concerning survival rates for patients
with cancer were obtained from the Swedish Cancer Registry
and presented as median survival and survival rates, both
with 95% confidence intervals (CI). All statistical analyses
were done in STATA version 14 (StataCorp LP).
Results
Study participants: basic characteristics, diagnoses, and
referral criteria
During the study period, 499 patients were referred to the
DC of whom 393 were eligible for diagnostic investigations
at the DC and 290 were eligible for study inclusion
(Figure 2). Of the included patients, 51.4% were women and
the median age was 69 years (IQR 16.6).
A total of 64 patients (22.1%) were diagnosed with cancer
at the DC, thus making malignancies the most common
diagnostic group. There were 186 patients (64.1%) diagnosed
with nonmalignant diseases. A total of 73 patients (25.2%)
had multiple diagnoses belonging to different diagnostic
groups (Table 1). In 40 patients (13.8%), no diagnosis
was found.
A graph showing all diagnostic groups is shown in
Figure 3. Among other diagnoses than cancer, musculoskel-
etal diseases were the most common affecting 59 (20%) of
all patients including 46 cases of autoimmune or degenera-
tive joint diseases. A total of 46 (16%) patients were diag-
nosed with gastrointestinal diseases, and 29 patients (10%)
had hematological diseases, 25 of which had anemia. A total
of 89% of the patients had a history of previous diagnoses
of importance for the DC-investigation (as judged by the DC-
physician) and the median number of previous diagnoses of
importance was 2 (IQR 2).
In 79 (27%) patients, the diagnosis set at the DC was part of
the patient’s medical history and in 6 (9%) of the 64 cancer
patients, the diagnosis reached was related to a previous can-
cer diagnosis, e.g. relapse in colon cancer or malignant melan-
oma. The most common malignant diagnoses were
hematological diseases, followed by lung cancer, colorectal
cancer, and metastases (Figure 4). Of the patients with cancer,
30 (47%) had infiltrating tumors (solid tumors with potential to
spread based on TNM-staging) and 13 (20%) were referred to
palliative care. Among patients diagnosed with cancer, the
median survival time after diagnosis was 1.4 years (CI 0.7–2.8).
The 1-year survival rate was 0.55 (CI 0.42–0.67) and the 3-year
survival rate was 0.36 (CI 0.23–0.48).
The most common referral criteria for all patients were
pathological laboratory values, weight loss, fatigue, and pain/
joint pain. The other two recommended referral criteria, pro-
longed fever and suspected metastasis, were less common
although suspected metastasis was more frequent among
patients diagnosed with cancer compared to patients with
other diagnoses and no cancer diagnosis (p¼ .01 and .046
respectively). Patients with cancer had more pathological lab
values compared to patients with no diagnosis (p¼ .02)
Patients referred to the DC 
n = 499 
Not included in the study, n = 103 
Reasons for not participating 
Patient declines participation  n = 23 
Patient does not speak Swedish   n = 15 
Psychological problems n = 21 
Patient does not fulfil referral criteria  n = 17 
Patient is too ill for outpatient investigation  n = 5 
Private referral n = 1 
Dementia n = 10  
Referral from other clinic than n = 10 
primary health care center    
Impaired hearing n = 1
Patients eligible 
n = 393 
Patients included in the study 
n = 290 
Patients not eligible for DC investigation 
n = 106
Figure 2. Flowchart of patients included in the study.
Table 1. Patient characteristics.
Age, median (IQR) 69 (16.6)
Sex, number (%)
Men 140 (48.3)
Women 149 (51.4)
Education, number (%)
Low (≤ 9 years) 113 (45.9)
Middle (10–12 years) 88 (35.8)
High (> 12 years) 43 (17.5)
Marital status, number (%)
Married/live together 168 (68.3)
Single 76 (30.9)
Born in Sweden, number (%)
Yes 232 (94.3)
No 13 (5.3)
Diagnosed with cancer at the DC, number (%)
Yes 64 (22.1)
No 225 (77.6)
Diagnosed with other diseases, not cancer, number (%) 186 (64.1)
No diagnosis, number (%) 40 (13.8)
Multiple diagnoses from different diagnostic groupsa, number (%) 73 (25.2)
aSee the diagnostic groups in Figure 3.
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(Table 2). Although not intended for DC-investigation, there
were occasional alarm symptoms in the referrals from the
primary healthcare centers among patients with cancer; one
case of hematuria, two cases of changed bowel habits and
one case of dysphagia.
Patients diagnosed with cancer tended to have more
symptoms at referral compared to patients who were not
diagnosed with cancer, with a statistically significant differ-
ence when compared to patients with no diagnosis
(p< .0001) (Table 2). It was the group with advanced cancer
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17
13
7 7
6
4 4 4
3
2 2 2 2
*
*Number of patients with hematological cancer
0
5
10
15
20
25
30
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
wi
th
 c
an
ce
r
He
ma
tol
og
ic
Lu
ng
Co
lor
ect
al
Me
tas
tas
es
Bla
dd
er/
kid
ne
y
Ca
nce
r o
f u
nkn
ow
n p
rim
ary
Liv
er/
pa
ncr
ea
tic
Mi
sce
llan
eo
us Sk
in
Co
nn
ect
ive
 tis
sue
s
Pro
sta
te
Ov
ari
al
Bre
as
t
Figure 4. Cancer diagnoses at the DC (patients = 64).
300 E. STENMAN ET AL.
disease that was driving this trend: patients with infiltrating
tumors had more symptoms than patients with non-infiltrat-
ing tumors or hematological cancers (p¼ .01) (data
not shown).
During diagnostic workup at the DC, classical alarm symp-
toms emerged in 26 patients that were later diagnosed with
cancer. These symptoms were, however, not necessarily asso-
ciated with respective cancer form. Fecal blood was found in
one patient with colon cancer, three patients with urinary
tract cancer had hematuria, a lump was found in seven
patients with cancer (different forms), changed bowel habits
were reported by a patient with pancreatic cancer, swollen
lymph nodes were detected in five patients with cancer (dif-
ferent forms) and an uneven prostate was detected at
inspection in one patient with prostate cancer. In addition,
36 patients with cancer were found to have anemia, which is
a general high risk symptom.
Patients diagnosed with cancer were older than
patients with no diagnosis (69.8 (IQR 11.3) and 63.4 (IQR
14.5) respectively, p¼ .01) and they had shorter patient
intervals (as assessed by the questionnaire: sought care
within three months from first symptom) compared to
patients with no diagnosis (44% and 25% respectively,
p¼ .01) (Table 2).
Of all patients, a total of 36% had completed the full
DC-package in primary care prior to referral to the DC.
Radiology before referral should consist of chest X-ray,
which was performed in 66% of patients and abdominal
ultrasound, which was performed in 57% of patients. A
minority of the patients (28%) had completed all recom-
mended investigations prior to DC referral. In the DC-pack-
age, the most common samples to take were P-Sodium
(66%) and P-PSA (65% of men), whereas less than 40% of
the patients were tested for Hepatitis A, blood infection,
Epstein-Barr virus and Cytomegalovirus infections (data
not shown).
Time intervals
Table 3 shows the length of the primary care interval, the
DC interval and the total diagnostic interval, expressed as
mean number of working days, standard deviations (SD) and
percentiles. The date for the first contact with primary care
was difficult to obtain with missing data in 116/290 (40%)
cases. The mean investigation time in primary care (phase 1)
was 32.6 (SD 37.5) days and the median time was 21 days.
The mean investigation time at the DC (phase 2) was 17.1
(SD 17.9) days; the median time was 11 days. For the total
diagnostic interval, the mean investigation time was 46.8 (SD
36.1) days and the median time was 37 days. In primary
care, 72/174 (41.4%) of the patients were investigated within
the scheduled time frame of 15 days. At the DC, 221/286
(77.3%) were investigated within the scheduled time frame
of 22 days, and 87/171 patients (50.9%) were investigated
within the total scheduled time frame of 37 days, i.e. from
first contact in primary care to diagnosis at the DC. Among
patients who were diagnosed with cancer, 45% fulfilled the
time goals in primary care, 83% at the DC and 56% fulfilled
the total time goal of 37 days (data not shown). A sensitivity
analysis - in which time for the most recent diagnosis was
used for all patients - was performed and this did not influ-
ence the findings.
In Supplementary Tables S1–S3, comparisons between
investigations that achieved the time goals with those who
did not are shown. There are also comparisons between the
10% longest and the 10% shortest investigation times. The
DC-physician’s documented reasons for long diagnostic inter-
vals are presented in Table S2.
Factors associated with the length of the primary
care interval
In primary care, there was a significant association between
fulfilling the time goal (15 days) and taking the complete
Table 2. Diagnoses at the DC.
Diagnosed with
cancer (n = 64)
Diagnosed with other
diseases, not
cancer (n = 186)
No diagnosis
(n = 40) p-valuea p-valueb
Age, median (IQR) 69.8 (11.3) 66.1 (13.9) 63.4 (14.5) .06 .01
Sex (men/women), % 58/42 47/53 40/58 .13 .10
Taken the complete DC-package before
referral, number (%)
16 (25) 74 (40) 15 (38) .03 .18
Sought care within 3 months from first
symptom, number (%)
28 (44) 73 (39) 10 (25) .16 .01
Investigational phase
Phase 1 (max 15 days), median (IQR) 21 (27.5) 22 (31) 20 (25) .17 .54
Phase 2 (max 22 days), median (IQR) 11 (14) 10 (16) 16 (19) .65 .02
Total (max 37 days), median (IQR) 32 (42) 38 (46) 31 (33) .20 .96
Symptoms
Fatigue, number (%) 20 (31) 65 (35) 13 (33) .59 .89
Weight loss, number (%) 29 (45) 70 (38) 19 (48) .28 .83
Pain/joint pain, number (%) 23 (36) 64 (34) 8 (20) .83 .08
Prolonged fever, number (%) 2 (3) 6 (3) 0 (0) .97 .26
Pathological lab values, number (%) 38 (59) 114 (61) 14 (35) .79 .02
Suspected metastasis, number (%) 12 (19) 14 (8) 2 (5) .01 .046
Number of symptoms (1, 2, > 2), % 13/41/47 24/35/41 50/28/23 .17 <.0001
Comparison between patients diagnosed with cancer, patients diagnosed with other diseases, not cancer, and patients with
no diagnosis.
ap-value for test between patients diagnosed with cancer and patients diagnosed with other diseases, not cancer.
bp-value for test between patients diagnosed with cancer and patients with no diagnosis.
ACTA ONCOLOGICA 301
DC-package (48.6% versus 30.4%, p¼ .02), and also with the
number of symptoms (p¼ .03) (Table S1). When examining
the 10% longest and 10% shortest primary care intervals,
patient interval was identified as a major factor; among
patients with the longest investigation times in primary care,
only one (5.3%) contacted the primary healthcare center
within three months from the first symptom compared to
65% among those with the shortest investigation times
(p< .001).
Factors associated with the length of the DC interval
No statistically significant associations were found when
comparing investigations that achieved time goals at the DC
with those who did not (Table S2).
When comparing the 10% longest with the 10% shortest
investigation times at the DC, factors that emerged with stat-
istical significance were female sex and getting no diagnosis:
women were in majority among patients with the longest
investigations and in minority among patients with the
shortest investigations (62% and 34% respectively; p¼ .03). A
total of 24.1% of patients with the longest investigation
times did not get a diagnosis as compared to only 2.9% of
patients with the shortest investigation times (p¼ .01).
Among patients with prolonged DC intervals (>22 days),
there were, in many cases, documented reasons, such as
waiting times at other clinics or need of observation time
(Table S2).
Factors associated with the length of the total
diagnostic interval
For the total diagnostic interval (primary careþDC), taking
the complete DC-package was significantly associated with
fulfilling the time goal (p¼ .03) (Table S3). Short patient
interval (seeking care within three months) was significantly
more common in the group with the 10% shortest investiga-
tions compared to the 10% longest (p¼ .02).
Patient experiences
Patients (n¼ 246) expressed a high degree of satisfaction
with their DC fast-track referral (Figure 5) with 86% valuing
their investigation at the DC as very good or excellent. A
total of 86% of patients answered that the treatment by the
healthcare staff was very good or excellent and 78% judged
the information given to be very good or excellent. A total
of 88% of patients felt listened to (always or almost always)
and 81% always or almost always understood answers to
their questions. A total of 85% of patients answered that the
investigation time at the DC was satisfactory, 2.4% remarked
that it was too long, and 10.6% thought that it was
too short.
Discussion
Our study evaluated the results of the first Swedish DC. The
center was established in 2012 in response to a lack of for-
mal diagnostic pathway for patients with nonspecific symp-
toms of serious disease, who were at risk of medically
unjustified delayed cancer diagnosis. Since 2016, the concept
has developed into a standardized care pathway for cancer.
Today, more than 20 DCs are distributed across Sweden. In
Denmark, where the concept was originally developed, each
of the five regions has at least one DC. In Norway, develop-
ment of DCs is part of the cancer strategy.
Using predefined referral criteria and a diagnostic package,
we demonstrated that 22% of the patients were diagnosed
with cancer with stable results during the study period. In eval-
uations of the Danish model, 13-22% of the patients were
diagnosed with cancer [20,21,25] and the aim is for a continu-
ing decrease [20]. The constant 22% cancer prevalence at the
Swedish DC may be a sign that family physicians can pinpoint
the ‘right’ patients, but it might also indicate that more
patients need to be referred. Using the present criteria for
referral, the chance of detecting cancer may, however, be lim-
ited since nonspecific, serious, symptoms often occur when
the cancer is advanced. Of the patients diagnosed with cancer
at the DC, 47% had infiltrating tumors, which was reflected in
the referral of 13 patients (20%) directly to specialized pallia-
tive care and a 3-year overall survival rate of 36%. Earlier detec-
tion of cancer may require other strategies such as screening
and efforts to improve awareness in the population about
early symptoms of cancer. Patients with an adverse prognosis
and a short remaining life span still belong to the DC’s target
groups and herein timely management with efficient access to
supportive and palliative care that reduces symptoms and
improves quality of life. Patients who are investigated without
any diagnosis identified represent another important target
group that benefits from the efficient and multidisciplinary
diagnostic workup that the DC concept offers. Exclusion of
defined and treatable diagnoses may allow for other interven-
tions such as physical activity or coping strategies.
Table 3. Number of days in each investigational phase (working days).
Primary care interval (max 15
days) (n = 174)a
DC interval (max 22 days)
(n = 286)b
Total diagnostic interval
(max 37 days) (n = 171)
Days, mean (SD) 32.6 (37.5) 17.1 (17.9) 46.8 (36.1)
Days, p10 3 3 13
Days, p25 10 5 22
Days, p50 21 11 37
Days, p75 41 21 65
Days, p90 80 40 92
Fulfilled time goal, number (%) 72 (41.4) 221 (77.3) 87 (50.9)
aFirst contact with primary care is missing for 116 patients.
bDate of diagnosis at the DC is missing for 4 patients.
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The tumor spectrum and the median age at diagnosis in
our study were similar to the results from the Danish DC
evaluations [20,21]. Among the cancers diagnosed, hemato-
logic malignancies, lung cancer and colorectal cancer predo-
minated; these findings concurred with the DC-findings in
Denmark [20]. The symptom spectrum identified was also
comparable to that observed at the Danish DCs with weight
loss, fatigue and pain among the five most common symp-
toms that were noted [20,21,25]. The symptoms agreed with
the recommended referral criteria and their appropriateness
was confirmed by a previous questionnaire survey about
family physicians’ views on the DC-project, in which 88% of
the responders thought the referral criteria to be adequate
(published in Swedish only). A possibility worthy of further
exploration relates to the potential among family physicians
to define serious disease by clinical intuition and to mark
this as a criterion for further diagnostic evaluation. Studies
have shown that family physicians’ gut feeling, or intuition,
can be highly predictive of cancer in patients with nonspe-
cific symptoms as well as palpable tumors and abdominal
symptoms and that the ability improves with the physician’s
age and experience. [21,26,27]. Consultancy frequency repre-
sents another criterion of interest for further study; an
increased frequency of consultancies has been documented
during the year prior to a diagnosis of cancer [28,29]. This
criterion has been included among the Danish cancer patient
pathway referral criteria for patients with nonspecific symp-
toms [23].
The time goal of 22 days for the DC interval was
reached in the majority of patients, whereas the time goal of
15 days for the primary care interval was reached only in a
minority of the investigations. Thus, in primary care, there
may be room for improvement regarding diagnostic time
intervals as well as adherence to the recommended work-
flow. Following the Danish experience with the purpose of
shortening investigation times, the DC-package was intro-
duced in the design of the project. However, taking a prede-
termined set of samples without specific indications was
much questioned among healthcare managers and family
physicians, whose traditional view is that each test or
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Figure 5. Patient questionnaire (patients = 246).
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examination should be ordered from a specific clinical suspi-
cion or question. This reluctance may explain the low rate of
complete DC-packages taken. But taking the complete DC-
package turned out to be associated with shorter diagnostic
intervals in our evaluation and may be a helpful complement
in the diagnostic process of this patient group. This is sup-
ported by observations that the probability of cancer in
patients with nonspecific, serious symptoms increased with
an increasing number of abnormal blood tests in a pre-
defined blood test panel [30]. Thus, further optimization and
evaluation is needed to define the best possible package.
Considering the challenge of implementing a new model at
42 primary healthcare centers, both private and public, a
time goal-fulfillment of 41% may be a reasonable interim
result, but with continuous communication and a stream-
lined model that is well anchored among the family physi-
cians, the share can hopefully increase.
In our study, patients diagnosed with cancer were older,
sought care earlier, and showed a greater number of symp-
toms compared to patients with no diagnosis. The DC-inter-
vals were, on average, shorter for patients diagnosed with
cancer. Additional analyses showed that few symptoms, lon-
ger patient intervals and lack of a final diagnosis were associ-
ated with prolonged diagnostic intervals. It may be worth
considering if the time goals for diagnostic centers should
target all referred patients or if investigations can be slightly
prolonged when cancer or other life threatening disease has
been ruled out.
A majority of the patients expressed positive experiences
from the DC-evaluation. They felt, in general, listened to and
understood the answers they got to their questions. A
slightly lesser share valued their care at the primary health-
care center as excellent compared to the DC. This is not sur-
prising, though, when you consider that the DC had time
and resources earmarked for the patient population. The pre-
viously mentioned family physician questionnaire showed
that 94% of the responders thought the DC to be advanta-
geous for patients and that 92% thought it to be advanta-
geous for the family physicians themselves. We choose to
complement the evaluation with ‘soft values’ via question-
naires since this is an important part of the implementation
process—the patients’ and healthcare providers’ points of
view should be, and are, central in decisions about future
priorities in healthcare. To get a deeper understanding of
patients and family physicians’ opinions, individual or focus
group interviews could be useful.
Strengths and limitations
A strength of the present study is the prospective design
and the consecutive inclusion of all patients referred to the
DC, irrespective of diagnosis. Data were continuously col-
lected and monitored. Since several analyses were performed
in a relatively heterogeneous patient material, some sub-
groups were of limited size. Another limitation is related to
the difficulty to collect data from primary care and thus the
uncertainty on date of first contact for which lack of records
implied missing data.
Conclusions
Our evaluation demonstrates that the DC concept represents
a well-functioning diagnostic pathway for patients with non-
specific, potentially serious symptoms. A diagnosis was
reached in 86.2% of the patients and the time goal for inves-
tigation at the DC was achieved in a majority of the patients
although the primary care intervals may still be shortened. A
revision of the model for the initial investigation should
therefore be considered. The diagnostic spectrum, patient
characteristics and frequency of cancer, along with a high
degree of patient satisfaction verify the feasibility of the
DC concept.
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